The long term goals are to elucidate the mechanisms that control new blood vessel growth - a process called angiogenesis - in the ovarian follicle and corpus luteum (CL). In the ovary, blood vessels undergo repeated and rapid growth and involution in conjunction with follicular growth and CL formation and regression. It is likely, that this vessel growth is controlled by the release of angiogenic factors from the granulosa cells of the developing follicle and from the cells of the CL - a mechanism analogous to that by which tumors recruit a blood supply. Rat ovarian tissue, for example, transplanted to the chorioallantoic membrane of the chick embryo induces new blood vessel formation and revascularizes; this revascularization is correlated with the functional status of the tissue, e.g., age of the CL. It was subsequently found that granulosa cells from preovulatory follicles of rats release potent endothelial cell mitogens when cultured in vitro. When cultured under hypoxic conditions, the cells release an additional high-MW factor that causes endothelial cells to lose their normal polygonal shape and assume an elongated morphology, resembling that of migrating endothelial cells. Furthermore, hypoxia induces the synthesis of specific proteins by granulosa cells and other cell types, a novel observation that could rapidly lead to the identification of hypoxia-induced angiogenic factors.
The specific aim of the present grant proposal are to: (I) Separate, characterize, purify, and identify the multiple angiogenic factors (endothelial cell effectors) present in or produced by rat granulosa cells and other ovarian tissues; (II) Evaluate the effects of mediators of ovarian function - gonadotropins, steroids, growth factors, glycosaminoglycans, etc. - on the production of these angiogenic factors; and (III) Determine the role of hypoxia in stimulating angiogenic factor production by granulosa cells. Identification of ovarian angiogenic factors and an understanding of how their production is controlled could lead to a better understanding of normal and abnormal ovarian function, as well as the pathological neovascularization that contributes to tumor growth, heart disease, and diabetic retinopathy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA045055-07
Application #
3188058
Study Section
Reproductive Biology Study Section (REB)
Project Start
1986-09-30
Project End
1990-03-31
Budget Start
1988-09-01
Budget End
1990-03-31
Support Year
7
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Kazi, Armina A; Jones, Jenny M; Koos, Robert D (2005) Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Mol Endocrinol 19:2006-19
Koos, Robert D; Kazi, Armina A; Roberson, Mark S et al. (2005) New insight into the transcriptional regulation of vascular endothelial growth factor expression in the endometrium by estrogen and relaxin. Ann N Y Acad Sci 1041:233-47
Rockwell, L Christie; Pillai, Suresh; Olson, C Erik et al. (2002) Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents. Biol Reprod 67:1804-10
Pillai, Suresh B; Jones, Jenny M; Koos, Robert D (2002) Treatment of rats with 17beta-estradiol or relaxin rapidly inhibits uterine estrogen receptor beta1 and beta2 messenger ribonucleic acid levels. Biol Reprod 67:1919-26
Hruska, Kathleen S; Tilli, Maddalena T; Ren, Shuxun et al. (2002) Conditional over-expression of estrogen receptor alpha in a transgenic mouse model. Transgenic Res 11:361-72
Pillai, S B; Rockwell, L C; Sherwood, O D et al. (1999) Relaxin stimulates uterine edema via activation of estrogen receptors: blockade of its effects using ICI 182,780, a specific estrogen receptor antagonist. Endocrinology 140:2426-9
Forsythe, J A; Jiang, B H; Iyer, N V et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-13
Koos, R D (1995) Increased expression of vascular endothelial growth/permeability factor in the rat ovary following an ovulatory gonadotropin stimulus: potential roles in follicle rupture. Biol Reprod 52:1426-35
Koos, R D; Banks, P K; Inkster, S E et al. (1993) Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 45:217-25
Cullinan-Bove, K; Koos, R D (1993) Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133:829-37

Showing the most recent 10 out of 17 publications